Nuvation Bio Inc. is a global biopharmaceutical company dedicated to tackling some of the greatest unmet needs in oncology through the development of differentiated and novel therapeutic candidates. Founded in 2018, the company leverages a deep understanding of cancer biology to build a pipeline of small molecule inhibitors and innovative drug-drug conjugates (DDCs). Nuvation Bio's portfolio is highlighted by its lead commercial asset, IBTROZI (taletrectinib), a next-generation ROS1 inhibitor designed for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The company's clinical pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor, and NUV-1511, the first clinical candidate from its proprietary DDC platform.
Historically a clinical-stage company, Nuvation Bio transitioned to a commercial entity following the FDA approval of IBTROZI. The company significantly expanded its late-stage oncology capabilities through the strategic acquisition of AnHeart Therapeutics in 2024. Revenue is primarily generated through licensing agreements and research and development services, such as its exclusive license agreement with Innovent Biologics for the commercialization of taletrectinib in Greater China.
Headquartered in New York with additional offices in San Francisco, Boston, and Shanghai, Nuvation Bio operates in a highly competitive oncology market. It positions itself against both established pharmaceutical giants and emerging biotech firms by focusing on indications where conventional therapies have failed or face drug resistance. The company's business model relies on advancing its proprietary pipeline through clinical trials, securing regulatory approvals, and forming strategic partnerships to commercialize its therapies globally.
